Abstract Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations. Here, we used data from a randomized phase II clin...
J. Hermansen, Weikaixin Kong, Andrea M. Brodersen et al.· HemaSphere· 0 citations
Cancer-associated fibroblasts (CAFs) promote tumorigenesis and represent potential therapeutic targets, highlighting the need for precise understanding of CAF heterogeneity. In colorectal cancer (CRC), CAF subsets and nomenclature vary widely, and many studies overlook the diversity of normal colon fibroblasts that sha...
Emma W. Viitala, Ella Salminen, Mitro Miihkinen et al.· Molecular Systems Biology· 0 citations
Pancreatic ductal adenocarcinoma (PDAC), with a 12% 5-year survival rate, is the most aggressive type of cancer. Early diagnosis for this pathology is rare, and conventional treatments such as surgery, radio- or chemotherapy, have little to no effect on reducing mortality. Machine learning (ML) approaches could be used...
Alejandra Paja-García, Rafael Romero-Becerra, T. Aittokallio et al.· PLoS Computational Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
